Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades

Stock Track

05/06

Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.

The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.

The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1155955988"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155955988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155955988?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155955988","market":"us","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades","media":"Stock Track","content":"<p>Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.</p><p>The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.</p><p>The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-06 23:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.</p><p>The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.</p><p>The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1155955988","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155955988","pubTimestamp":1778079731,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.The surge follows the release of Veracyte's first-quarter 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"个股追踪|Veracyte盘中飙升17.77%，因Q1盈利强劲、指引上调和分析师升级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}